Atea Pharmaceuticals, Inc. Operating Lease, Expense
Atea Pharmaceuticals, Inc. (AVIR) reported Operating Lease, Expense of $646.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-03-05
- Atea Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2020-12-31 was $92.00K, a 2.13% decline year-over-year.
- Atea Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2020-09-30 was $70.00K, a 0.00% change year-over-year.
- Atea Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-12-31 was $94.00K.
- Atea Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-09-30 was $70.00K.
- Atea Pharmaceuticals, Inc. operating lease, expense for fiscal 2025 was $646.00K, a 0.00% change from fiscal 2024.
- Atea Pharmaceuticals, Inc. operating lease, expense for fiscal 2024 was $646.00K, a 0.00% change from fiscal 2023.
- Atea Pharmaceuticals, Inc. operating lease, expense for fiscal 2023 was $646.00K, a 20.35% decline from fiscal 2022.
- Atea Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $811.00K, a 155.03% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $646.00K 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $646.00K 10-K · filed 2026-03-05 | |||
| 2023-12-31 | $646.00K 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $811.00K 10-K · filed 2024-02-28 | |||
| 2021-12-31 | $318.00K 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $162.00K derived: sum of 2 quarters · filed 2023-02-28 | $303.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $70.00K 10-Q · filed 2020-12-10 | $211.00K 10-Q · filed 2020-12-10 | ||
| 2019-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $164.00K derived: sum of 2 quarters · filed 2022-02-28 | $305.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $70.00K 10-Q · filed 2020-12-10 | $211.00K 10-Q · filed 2020-12-10 | ||
| 2018-12-31 | $316.00K 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |